Key result
E. coli hemolysin triggers acute coronary vasoconstriction and ventricular fibrillation, preventable by MK-886.
Why the study?
Escherichia coli hemolysin is implicated as an important pathogenic factor in extraintestinal infections including sepsis, prompting investigation into the effects of its coronary administration on cardiac function.
Does coronary administration of Escherichia coli hemolysin impair cardiac function and cause coronary vasoconstriction in isolated perfused rat hearts?
Does coronary administration of Escherichia coli hemolysin impair cardiac function and cause coronary vasoconstriction in isolated perfused rat hearts?
Low doses of E. coli hemolysin induce severe coronary vasoconstriction, loss of myocardial contractility, and electrical instability in isolated rat hearts via leukotriene generation, suggesting a potential mechanism for cardiac dysfunction in septic shock.
Objective hemolysin has been implicated as an important pathogenic factor in extraintestinal infections including sepsis. We investigated the effects of coronary administration of hemolysin on cardiac function in isolated rat hearts perfused at constant flow. Design Prospective, experimental study. Setting Research laboratory at a university hospital. Subjects Isolated hearts from male Wistar rats. Interventions Isolated hearts were perfused with purified hemolysin for 60 min. Measurements and main results Low concentrations of the toxin in the perfusate (0.1-0.2 hemolytic units/mL) caused a dose-dependent coronary vasoconstriction with a marked increase in coronary perfusion pressure, which was paralleled by a decrease in left ventricular developed pressure (and the maximum rate of left ventricular pressure increase). Moreover, 0.2 hemolytic units/mL hemolysin evoked ventricular fibrillation within 10 mins of toxin application. These events were accompanied by the liberation of leukotrienes (LTC4, LTD4, LTE4, and LTB4), thromboxane A2, prostaglandin I2, and the cell necrosis markers lactate dehydrogenase and creatine kinase into the recirculating perfusate. The lipoxygenase inhibitor MK-886 fully blocked the toxin-induced coronary vasoconstrictor response and the loss of myocardial contractility and reduced the release of lactate dehydrogenase and creatine kinase. In contrast to this, the cyclooxygenase inhibitor indomethacin was entirely ineffective. In addition, hemolysin elicited an increase in heart weight and left ventricular end-diastolic pressure, the latter again being suppressed by MK-886. Conclusions Low doses of hemolysin cause strong coronary vasoconstriction, linked with loss of myocardial performance, release of cell injury enzymes, and electrical instability, with all events being largely attributable to toxin-elicited leukotriene generation in the coronary vasculature. Bacterial exotoxins such as hemolysin thus may be implicated in the cardiac abnormalities encountered in septic shock.
No takes yet. Share an insight, caveat, or question.
Sibelius et al. (2003) studied Escherichia coli hemolysin-induced cardiac dysfunction / septic shock model. Purified Escherichia coli hemolysin (with or without MK-886 or indomethacin) vs. MK-886 (lipoxygenase inhibitor) and indomethacin (cyclooxygenase inhibitor) was evaluated on Coronary vasoconstriction (coronary perfusion pressure) and myocardial contractility (left ventricular developed pressure). Escherichia coli hemolysin (0.1-0.2 hemolytic units/mL) caused dose-dependent coronary vasoconstriction, loss of contractility, and ventricular fibrillation within 10 min, which was blocked by MK-886.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: